
簡要描述:Chloropyramine hydrochloride 6170-42-9Chloropyramine is a first generation antihistamine drug approved in some Eastern European countries for the treatment of allergic conjunctivitis, allergic rhini
產(chǎn)品分類
Product Category詳細(xì)介紹
| 品牌 | absin | CAS | 6170-42-9 |
|---|---|---|---|
| 分子式 | C16H20ClN3.HCl | 純度 | >98% |
| 分子量 | 326.26 | 貨號 | abs47026952 |
| 規(guī)格 | 25mg | 供貨周期 | 現(xiàn)貨 |
| 主要用途 | and anaphylactic shock. | 應(yīng)用領(lǐng)域 | 化工,生物產(chǎn)業(yè),農(nóng)林牧漁,制藥/生物制藥,綜合 |
Chloropyramine hydrochloride 6170-42-9
| 產(chǎn)品描述 | |
| 描述 | Chloropyramine is a first generation antihistamine drug approved in some Eastern European countries for the treatment of allergic conjunctivitis, allergic rhinitis, bronchial asthma, and other atopic (allergic) conditions. Related indications for clinical use include Quincke’s edema, allergic reactions to insect bites, food and drug allergies, and anaphylactic shock. |
| 純度 | >98% |
| 儲存/保存方法 | Store at -20℃ for one year(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution. |
| 基本信息 | |
| 別名 | yan酸氯吡胺 |
| 外觀 | 白色至類白色結(jié)晶性粉末 |
| 可溶性/溶解性 | DMSO : 30 mg/mL (91.95 mM; Need ultrasonic and warming) |
| 生物活性 | |
| 靶點(diǎn) | FAK-VEGFR-3,H1 receptor |
| In vitro(體外研究) | BT474 cells are highly sensitive to Chloropyramine hydrochloride (compound 1) treatment, whereby 1 µM concentrations cause a 40% reduction of viability after 48 h of treatment. It is found that at 1 µM concentrations of Chloropyramine hydrochloride, viability of control MCF7-pcDNA3 cells is significantly higher than the viability of MCF7-VEGFR-3 cells (P. |
| In vivo(體內(nèi)研究) | Chloropyramine hydrochloride causes a dramatic reduction of tumor growth in both model systems whereby the tumor size in the treated groups is approximately 20% of the tumor size in vehicle control groups. Doxorubicin administered at 3 mg/kg causes approximately 60% reduction of tumor growth, but has no effect on tumor growth at 0, 3 mg/kg. In contrast, there is a modest effect of Chloropyramine hydrochloride alone (50% reduction of tumor growth). The low-dose combination of Chloropyramine hydrochloride and doxorubicin has a prolonged anti-tumor effect (85% reduction of tumor growth) that is greater than either drug alone. |
| 參考文獻(xiàn) | |
| 參考文獻(xiàn) |
|
| 研究領(lǐng)域 | |
| 研究領(lǐng)域 | CancerSignal transductionProtein phosphorylationTyrosine kinasesFAK family CardiovascularAngiogenesisAdhesion / ECMIntegrins Signal TransductionCytoskeleton / ECMExtracellular MatrixStructuresFocal Adhesions Signal TransductionProtein PhosphorylationTyrosine KinasesFAK / PYK Drug DiscoverySmall Molecule DrugLead Compound Discovery |
產(chǎn)品咨詢
